The study aims to assess the efficacy, safety and tolerability of cenicriviroc versus the comparator regimen in 150 HIV-1-infected, patients with antiretroviral treatment-naive with only CCR5-tropic virus. In
VAC-3S is designed to fight the pathogenicity of the virus by blocking the decrease of the CD4 + T lymphocytes cell count. The VAC-3S project was supported by
Scil Technology, a company engaged in drug development, formulation and analytics, is a wholly owned subsidiary of BioNet Holding. Scil Technology CEO Christian Nafe said the grant will
A subsidiary of Japan-based global specialty pharmaceutical company Kyowa Hakko Kirin, ProStrakan aims to introduce Rectiv in the first quarter of 2012 in the US. Marketed under the
P2D Bioscience said preclinical testing and numerous scientific publications indicate that PD2007 inhibits dopamine transport in multiple brain regions. The company said, in addition to its inhibiting activity,
As part of the neuroscience therapeutic area partnership, which is now expanded to cardiovascular and metabolic diseases, Jubilant will deliver a steady stream of preclinical outcomes to AstraZeneca.
In the trial, the company has recruited around 300 patients at around 40 sites in the US. The Phase IIb trial, which is a randomized, double blind and
The Phase II trial which is a randomized, double blind, placebo-controlled study, aims to evaluate the safety and efficacy of GLYX-13 in treatment-resistant depression. Naurex intends to recruit
Natco had earlier submitted an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) to market GSK’s generic version of Tykerb 250mg tablets. Tykerb
Levaquin is a synthetic broad spectrum antibacterial agent used to treat or prevent infections caused by susceptible bacteria. Lupin operates in Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.